Association between handling of pet treats and infection with Salmonella enterica serotype newport expressing the AmpC beta-lactamase, CMY-2.
Resistance to the extended-spectrum cephalosporins can occur in Salmonella species via the production of extended-spectrum and AmpC beta-lactamases. We describe human infections with Salmonella enterica serotype Newport phage type 14 strains resistant to ceftazidime (CAZ) and cefoxitin (FOX) related to the handling of pet treats containing dried beef. These strains were isolated from five patients in Calgary, Alberta, Canada, during 2002 and were compared to a strain cultured from a commercial pet treat present at the property of one of the patients. The strains were resistant to FOX, CAZ, cefpodoxime, ampicillin, and chloramphenicol; intermediate resistant to ceftriaxone and cefotaxime; and sensitive to the aminoglycosides, ciprofloxacin, cefepime, and imipenem. Isoelectric focusing, multiplex PCR, and sequencing of the amplicons showed that all strains produced the plasmid-encoded AmpC beta-lactamase, CMY-2. Restriction analysis of plasmid DNA following transformation demonstrated that bla(CMY-2) was encoded on an approximately 140-kb plasmid. Pulsed-field gel electrophoresis showed the human and pet treat Salmonella strains to be highly related. This study is the first to implicate the transfer of multidrug-resistant Salmonella species through the handling of commercial pet treats containing animal products. In addition to documenting the first cases of human infection caused by CMY-2-producing S. enterica serotype Newport strains in Canada, this study illustrates the necessity of rapid and accurate laboratory-based surveillance in the identification of novel types of antimicrobial resistance.
Pitout
Johann D D
JD
Division of Microbiology, Calgary Laboratory Services and Department of Pathology & Laboratory Medicine, University of Calgary, Calgary, Alberta, Canada. johann.pitout@cls.ab.ca
Reisbig
Mark D
MD
Mulvey
Mike
M
Chui
Linda
L
Louie
Marie
M
Crowe
Larry
L
Church
Deirdre L
DL
Elsayed
Sameer
S
Gregson
Dan
D
Ahmed
Rafiq
R
Tilley
Peter
P
Hanson
Nancy D
ND
D000328:Adult; D000416:Alberta / Q000453:epidemiology; D000821:Animal Feed / Q000382:microbiology*; D000818:Animals; D000829:Animals, Domestic; D001434:Bacteriophage Typing; D002417:Cattle; D002418:Cattle Diseases / Q000382:microbiology; D002440:Cefoxitin / Q000494:pharmacology; D002442:Ceftazidime / Q000494:pharmacology; D018550:Cephalosporin Resistance; D002511:Cephalosporins / Q000494:pharmacology; D002675:Child, Preschool; D016521:Electrophoresis, Gel, Pulsed-Field; D005260:Female; D006801:Humans; D007223:Infant; D008297:Male; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D011159:Population Surveillance; D012480:Salmonella Infections / Q000453:epidemiology / Q000382:microbiology* / Q000635:transmission; D012481:Salmonella Infections, Animal / Q000382:microbiology; D019779:Salmonella enterica / Q000145:classification / Q000187:drug effects / Q000201:enzymology* / Q000235:genetics; D012703:Serotyping; D001618:beta-Lactamases / Q000378:metabolism*
D002511:Cephalosporins; D002440:Cefoxitin; D002442:Ceftazidime; C103022:beta-lactamase CMY-2; D001618:beta-Lactamases